Abstract:During the last thirty years since the discovery of endothelin-1, the therapeutic strategy that has evolved in the clinic, mainly in the treatment of pulmonary arterial hypertension, is to block the action of the peptide either at the ET(A) subtype or both receptors using orally active small molecule antagonists. Recently, there has been a rapid expansion in research targeting ET receptors using chemical entities other than small molecules, particularly monoclonal antibody antagonists and selective peptide agonists and antagonists. While usually sacrificing oral bio-availability, these compounds have other therapeutic advantages with the potential to considerably expand drug targets in the endothelin pathway and extend treatment to other pathophysiological conditions. Where the small molecule approach has been retained, a novel strategy to combine two vasoconstrictor targets, the angiotensin AT(1) receptor as well as the ET(A) receptor in the dual antagonist sparsentan has been developed. A second emerging strategy is to combine drugs that have two different targets, the ET(A) antagonist ambrisentan with the phosphodiesterase inhibitor tadalafil, to improve the treatment of pulmonary arterial hypertension. The solving of the crystal structure of the ET(B) receptor has the potential to identify allosteric binding sites for novel ligands. A further key advance is the experimental validation of a single nucleotide polymorphism that has genome wide significance in five vascular diseases and that significantly increases the amount of big endothelin-1 precursor in the plasma. This observation provides a rationale for testing this single nucleotide polymorphism to stratify patients for allocation to treatment with endothelin agents and highlights the potential to use personalized precision medicine in the endothelin field.

Molecular Determinants for Ligand Selectivity of the Cell-Free Synthesized Human Endothelin B Receptor

Structural Insights into Angiotensin Receptor Signaling Modulation by Balanced and Biased Agonists.

Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor.

Structural basis of peptide recognition and activation of endothelin receptors

Single Hormone or Synthetic Agonist Induces G S /G I Coupling Selectivity of EP Receptors Via Distinct Binding Modes and Propagating Paths

Structural basis of antagonist selectivity in endothelin receptors

Crystal structures of human ETB receptor provide mechanistic insight into receptor activation and partial activation

Expression and purification of an engineered human endothelin receptor B in a monomeric form

Pharmacophore Modeling of Dual Angiotensin II and Endothelin A Receptor Antagonists.

Constrained catecholamines gain β2AR selectivity through allosteric effects on pocket dynamics

Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies.

Selective Polypeptide Ligand Binding to the Extracellular Surface of the Transmembrane Domains of the Class B GPCRs GLP-1R and GCGR

Modulation of G-protein coupled receptor sample quality by modified cell-free expression protocols: a case study of the human endothelin A receptor

Angiotensin II cyclic analogs as tools to investigate AT1R biased signaling mechanisms

Divergent Transducer-specific Molecular Efficacies Generate Biased Agonism at a G Protein-coupled Receptor (GPCR)

Screening and evaluation of the hit compound from a DNA-encoded library derived from natural products based on immobilized endothelin receptor A

Molecular mechanism of the endothelin receptor type B interactions with Gs, Gi, and Gq

Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12

Elucidation and refinement of synthetic receptor mechanisms

Molecular determinants of ligand efficacy and potency in GPCR signaling

New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine